Medical Devices
Medtronic MiniMed Paradigm Quick-Set Infusion Sets
| Recall Class: | Class I |
| Date Recall Initiated: | June 29, 2009 |
| Product: | Paradigm Quick-Set Infusion Sets, Models MMT-396, MMT-397, MMT-398, and MMT-399 (with lot numbers beginning with “8,” for example 8XXXXXX) The lot number is clearly marked on both the product label, and on each individual infusion set package. Only “Lot 8” Paradigm Quick-set infusion sets are affected by this recall. These devices were manufactured and distributed from December 1, 2007 through June 18, 2009. |
| Use: | An infusion set is a thin plastic tube used to deliver insulin from an insulin pump to a diabetes patient. |
| Recalling Firm: | Medtronic MiniMed 18000 Devonshire Street Northridge, California 91325 |
| Reason for Recall: | These infusion sets may not allow the insulin pump to vent air pressure properly. This could potentially result in the device delivering too much or too little insulin and may cause serious injury or death. |
| Public Contact: | The company may be contacted anytime, 24 hours a day, seven days a week. Physicians:
Patients/Customers:
See additional information under Useful Links below. |
| FDA District: | Los Angeles |
| FDA Comments: | Patients should stop using “Lot 8” Quick-set infusion sets. From July 6-9, 2009, the company sent letters to healthcare professionals, distributors, active customers and patients (sets purchased after January 1, 2009) and inactive customers (sets purchased before January 1, 2009). Active patients and customers received one box of replacement sets with their letters. Letters to patients and customers included instructions to:
Letters to distributors who purchased the affected devices included directions to:
Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these products will cause serious injury or death. Health care professionals and consumers may report adverse reactions or quality problems experienced with the use of these products to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by FAX. Useful Links: |







